tbuckley/cabot-search huggingface dataset:
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
Authors: Carey K Anders, Mark G Woodcock, Amanda E D Van Swearingen, Dominic T Moore, Maria J Sambade, Sonia Laurie, Alexander Robeson, Oleg Kolupaev, Luz A Cuaboy, Amy L Garrett, Karen McKinnon, Kristen Cowens, Dante Bortone, Benjamin C Calhoun, Alec D Wilkinson, Lisa Carey, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, E Claire Dees, Benjamin G Vincent, Jonathan S Serody
Journal: Journal for ImmunoTherapy of Cancer (2022)

Triple negative breast cancer (TNBC) is characterized by the presence of immune cells in the tumor microenvironment, however, the response to single-agent immune checkpoint inhibitor (ICI) therapy is modest. Preclinical models have demonstrated that intratumoral regulatory T cells (Tregs) dampen the antitumor response to ICI. We performed a single-arm phase II trial to evaluate the efficacy of a single low dose of cyclophosphamide (Cy) to deplete Tregs administered before initiating pembrolizumab. 40 patients with pretreated metastatic TNBC were enrolled. The primary endpoints were progression-free survival (PFS) and change in peripheral blood Tregs after Cy. Secondary endpoints included overall response rate (ORR), duration of response, overall survival, treatment-related adverse events (AEs), and correlative evaluations. Median PFS was 1.8 months, and the ORR was 21%. Tregs were not significantly decreased after Cy prior to ICI (-3.3%, p=0.19), and increased significantly after the first cycle of therapy (+21% between cycles 1 and 2, p=0.005). Immune-related AEs were similar to historical pembrolizumab monotherapy, and were associated with response to therapy (p=0.02). Patients with pretreatment tumors harboring increased expression of B cell metagene signatures and increased circulating B cell receptor repertoire diversity were associated with clinical response and immune-related toxicity (IRT). Among patients with heavily pretreated TNBC, Cy prior to pembrolizumab did not significantly deplete Tregs, and in those with decreased numbers there was rapid recovery following therapy. Increased B cell gene expression in baseline samples was associated with clinical response and IRT.
Reducing relapse and accelerating osteogenesis in rapid maxillary expansion using an injectable mesoporous bioactive glass/fibrin glue composite hydrogel
Authors: Hanjiang Zhao, Xiangyu Wang, Anting Jin, Minjiao Wang, Zeying Wang, Xingtai Huang, Jiewen Dai, Xudong Wang, Dan Lin, Steve GF. Shen
Journal: Bioactive Materials (2022)
Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study
Authors: Linda-Gail Bekker, Nigel Garrett, Ameena Goga, Lara Fairall, Tarylee Reddy, Nonhlanhla Yende-Zuma, Reshma Kassanjee, Shirley Collie, Ian Sanne, Andrew Boulle, Ishen Seocharan, Imke Engelbrecht, Mary-Ann Davies, Jared Champion, Tommy Chen, Sarah Bennett, Selaelo Mametja, Mabatlo Semenya, Harry Moultrie, Tulio de Oliveira, Richard John Lessells, Cheryl Cohen, Waasila Jassat, Michelle Groome, Anne Von Gottberg, Engelbert Le Roux, Kentse Khuto, Dan Barouch, Hassan Mahomed, Milani Wolmarans, Petro Rousseau, Debbie Bradshaw, Michelle Mulder, Jessica Opie, Vernon Louw, Barry Jacobson, Pradeep Rowji, Jonny G Peter, Azwi Takalani, Jackline Odhiambo, Fatima Mayat, Simbarashe Takuva, Lawrence Corey, Glenda E Gray, William Brumskine, Nivashnee Naicker, Disebo Makhaza, Vimla Naicker, Logashvari Naidoo, Elizabeth Spooner, Elane van Nieuwenhuizen, Kathryn Mngadi, Maphoshane Nchabeleng, James Craig Innes, Katherine Gill, Friedrich Georg Petrick, Shaun Barnabas, Sharlaa Badal-Faesen, Sheetal Kassim, Scott Hayden Mahoney, Erica Lazarus, Anusha Nana, Rebone Molobane Maboa, Philip Kotze, Johan Lombaard, Daniel Rudolf Malan, Sheena Kotze, Phuthi Mohlala, Amy Ward, Graeme Meintjes, Dorothea Urbach, Faeezah Patel, Andreas Diacon, Khatija Ahmed, Coert Grobbelaar, Pamela Mda, Thozama Dubula, Angelique Luabeya, Musawenkosi Bhekithemba Mamba, Lesley Burgess, Rodney Dawson
Journal: The Lancet (2022)

We aimed to assess the effectiveness of a single dose of the Ad26.COV2.S vaccine (Johnson & Johnson) in health-care workers in South Africa during two waves of the South African COVID-19 epidemic.
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
Authors: David T. Teachey, Meenakshi Devidas, Brent L. Wood, Zhiguo Chen, Robert J. Hayashi, Michelle L. Hermiston, Robert D. Annett, J. Hunter Archer, Barbara L. Asselin, Keith J. August, Steve Y. Cho, Kimberly P. Dunsmore, Brian T. Fisher, Jason L. Freedman, Paul J. Galardy, Paul Harker-Murray, Terzah M. Horton, Alok I. Jaju, Allison Lam, Yoav H. Messinger, Rodney R. Miles, Maki Okada, Samir I. Patel, Eric S. Schafer, Tal Schechter, Neelam Singh, Amii C. Steele, Maria Luisa Sulis, Sarah L. Vargas, Stuart S. Winter, Charlotte Wood, Patrick Zweidler-McKay, Catherine M. Bollard, Mignon L. Loh, Stephen P. Hunger, Elizabeth A. Raetz
Journal: Journal of Clinical Oncology (2022)

To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III clinical trial AALL1231, which also attempted to reduce the use of prophylactic cranial radiation (CRT) in newly diagnosed T-ALL.
Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial
Authors: Gerard J. Criner, Frederick M. Lang, Robert L. Gottlieb, Kusum S. Mathews, Tisha S. Wang, Todd W. Rice, Deepu Madduri, Shashi Bellam, Robert Jeanfreau, Amy H. Case, Marilyn K. Glassberg, George Marshall Lyon, Kareem Ahmad, Robert Mendelson, J. Michael DiMaio, MaryAnn P. Tran, Cedric W. Spak, Jamil A. Abbasi, Steven G. Davis, Shekhar Ghamande, Steven Shen, Lisa Sherman, Simon Lowry
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

GM-CSF (granulocyte-macrophage colony-stimulating factor) has emerged as a promising target against the hyperactive host immune response associated with coronavirus disease (COVID-19).
THIRTY-DAY READMISSION RATES AND CAUSES AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION: INSIGHTS FROM THE NATIONWIDE READMISSIONS DATABASE: 2016-2018
Authors: Amandeep Goyal, Harsh Mehta, Poonam Bhyan, Tarun Dalia, Neelkumar Patel, Prakash Acharya, Suveenkrishna Pothuru, Andrew Sauer, Matthew Danter, Andrija Vidic, Travis Abicht, Zubair Shah
Journal: Journal of the American College of Cardiology (2022)
CORONARY ARTERY CALCIFICATIONS IN COVID-19 SURVIVORS: ASSOCIATION WITH MYOCARDIAL INJURY AND FUNCTION AFTER 6 WEEKS
Authors: R.A. Groen, M.A. de Graaf, J.W. Jukema, M.J. Schalij, J.L. Stöger, M.L. Antoni
Journal: Journal of the American College of Cardiology (2022)
Multimodality Imaging to Assess Leaflet Height in Mitral Bioprosthetic Valves
Authors: Mariama Akodad, Janarthanan Sathananthan, Georgios Tzimas, Hannah Salcudean, Mark Hensey, Gaurav S. Gulsin, David Meier, Ming-yu (Anthony) Chuang, Andrew G. Chatfield, Uri Landes, Philipp Blanke, Lars Sondergaard, Geoffrey W. Payne, Georg Lutter, Thomas Puehler, David A. Wood, John G. Webb, Jonathon A. Leipsic, Stephanie L. Sellers
Journal: JACC. Cardiovascular imaging (2022)
Abstract ES6-2: CDK4/6 for ER+
Authors: IA Mayer
Journal: Cancer Research (2022)

Abstract Hormone receptor positive (HR+) breast cancer is the most common subtype of breast cancer. A reasonable proportion of HR+ tumors recur during or following adjuvant endocrine therapy, and late recurrences (beyond 10 years from diagnosis) are not uncommon. The CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib were approved in combination with endocrine therapy for the treatment of first and second-line metastatic HR+ breast cancer, based on impressive improvements in progression-free survival and overall survival. Therefore, transitioning these drugs to the adjuvant setting in high-risk patients made sense, to further prevent short and long-term metastatic recurrence of HR+ breast cancer. To date, 3 of the 4 phase III clinical trials with CDK4/6 inhibitors in the adjuvant setting have been reported, with mixed results. Penelope-B and PALLAS, both exploring the use of palbociclib for 1 and 2 years, respectively, along with endocrine therapy in patients with high-risk clinical characteristics failed to demonstrate a benefit in 4-years and 2-years disease-free survival (DFS), despite an early signal of benefit in the Penelope-B trial at 2-years. The Monarch-E trial, using abemaciclib for 2 years along with endocrine therapy for patients with very high anatomical and biologic recurrence risk, has shown a 3% higher 2-years DFS than endocrine therapy alone, but follow-up is quite short (19 months), and it is unclear if it will be maintained over time. The NATALEE trial, using ribociclib for 3 years with endocrine therapy is expected to yield results in 2025. These data highlight several questions that remained unanswered. Are the CDK4/6 inhibitors different from each other despite an identical mechanism of action? Does duration of treatment matter? Does disease biology matter? Discontinuation rates, albeit different between these trials, seems to be an unlikely answer for the discrepant results. Fortunately, all these adjuvant trials have collected a rich biorepository of tissue and blood, which allows the investigators to better ellucidate unique biomarkers that may predict individual benefit for each of the approved CDK4/6 inhibitors, that will hopefully guide optimal patient selection and treatment combinations. Till then, longer follow-up on the Monarch-E and NATALEE trials are necessary to explore if CDK4/6 inhibitors should or not be incorporated to endocrine therapy in the adjuvant setting for patients at high-risk of metastatic recurrence. Citation Format: IA Mayer. CDK4/6 for ER+ [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES6-2.
UNGUIDED VERSUS GUIDED ALTERATION OF DUAL ANTIPLATELET THERAPY AFTER ACUTE CORONARY SYNDROME: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Authors: Tomohiro Fujisaki, Toshiki Kuno, Satoshi Shoji, Yuki Sahashi, Hisato Takagi, Alexandros Briasoulis, Pierre Deharo, Thomas Cuisset, Azeem Latib, Shun Kohsaka
Journal: Journal of the American College of Cardiology (2022)
Outdoor air pollution exposure and cognitive performance: findings from the enrolment phase of the CONSTANCES cohort
Authors: Mohammad Javad Zare Sakhvidi, Jun Yang, Emeline Lequy, Jie Chen, Kees de Hoogh, Noémie Letellier, Marion Mortamais, Anna Ozguler, Danielle Vienneau, Marie Zins, Marcel Goldberg, Claudine Berr, Bénédicte Jacquemin
Journal: The Lancet Planetary Health (2022)

BackgroundAir pollution exposure is one of the modifiable risk factors of cognitive decline. We aimed to test the association between exposure to several outdoor air pollutants and domain-specific cognitive performance.MethodsIn this cross-sectional study, we used data from the enrolment phase of the French CONSTANCES cohort. From the 220 000 people (aged 18–69 years) randomly recruited in the French CONSTANCES cohort, participants aged 45 years old or older (104 733 people) underwent a comprehensive cognitive assessment (verbal episodic memory, language skills, and executive functions). After exclusion of those who were not suitable for our analysis, 61 462 participants with available data were included in the analyses. We used annual mean concentrations at residential addresses, derived from land-use regression models, to assign exposure to particulate matter with aerodynamic diameters less than 2·5 μm (PM2·5), nitrogen dioxide (NO2), and black carbon. We used multiple linear regression models with different covariate adjustments to test the associations between each pollutant and cognitive outcomes. We did several sensitivity analyses, including multilevel modelling, meta-analysis by centre of recruitment, and exclusion of specific population groups.FindingsWe found significantly poorer cognitive function, especially on semantic fluency and domains of executive functions, with an increase in exposure to black carbon and NO2. Exposure to PM2·5 was mainly significant for the semantic fluency test. We found that decrease in cognitive performance with an increase of one interquartile range of exposure ranged from 1% to nearly 5%. The largest effect size (percentage decrease) for both PM2.5 and NO2 was found for the semantic fluency test (PM2.5 4·6%, 95% CI 2·1–6·9 and NO2 3·8%, 1·9–5·7), whereas for black carbon, the largest effect size was found for the digit symbol substitution test of the domains of executive functions (4·5%, 2·7–6·3). Monotonic and linear exposure–response associations were found between air pollution exposure and cognitive performance, starting from a low level of exposures.InterpretationSignificantly poorer cognitive performance was associated with exposure to outdoor air pollution even at low levels of exposure. This highlights the importance of further efforts to reduce exposure to air pollution.FundingThe Caisse Nationale d'Assurance Maladie, and partly funded by Merck Sharp & Dohme and L'Oréal, the French National Research Agency, and Fondation de France.TranslationFor the French translation of the abstract see Supplementary Materials section.
SEVERE ANEMIA AND LEUKOPENIA AS INITIAL MANIFESTATION OF PARVOVIRUS-B19 INFECTION IN A PATIENT WITH ORTHOTOPIC HEART TRANSPLANT
Authors: Sergio Jiménez, Amada Alvarez, Antonio Jordan-Rios, Carlos Guizar, Arturo Mendez, Rimsky Julian Bassa-Garrido, Cristopher Cándido Sanchez-Rodriguez
Journal: Journal of the American College of Cardiology (2022)
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Authors: Edward M Vital, Joan T Merrill, Eric F Morand, Richard A Furie, Ian N Bruce, Yoshiya Tanaka, Susan Manzi, Kenneth C Kalunian, Rubana N Kalyani, Katie Streicher, Gabriel Abreu, Raj Tummala
Journal: Annals of the Rheumatic Diseases (2022)

Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups. Methods We performed post hoc analyses of pooled data from the 52-week phase III TULIP-1/TULIP-2 placebo-controlled trials of intravenous anifrolumab in moderate-to-severe SLE. Outcomes were assessed in predefined subgroups: IFNGS (high/low), age, sex, body mass index, race, geographic region, age of onset, glucocorticoid use, disease activity and serological markers. Results In pooled data, patients received anifrolumab 300 mg (360/726) or placebo (366/726); 82.6% were IFNGS-high. IFNGS-high patients had greater baseline disease activity and were more likely to have abnormal serological markers versus IFNGS-low patients. In the total population, a greater proportion of patients treated with anifrolumab versus placebo achieved British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response at week 52 (difference 16.6%; nominal p&lt;0.001). BICLA response treatment differences with anifrolumab versus placebo were comparable to the total population across most predefined subgroups, including subgroups for baseline glucocorticoid dosage (&lt;10/≥10 mg/day prednisone/equivalent) and for clinical disease activity (SLE Disease Activity Index 2000 score &lt;10/≥10). Subgroups with larger treatment differences included IFNGS-high patients (18.2%), patients with abnormal baseline serological markers (23.1%) and Asian patients (29.2%). The safety profile of anifrolumab was similar across subgroups. Conclusions Overall, this study supports the consistent efficacy and safety of anifrolumab across a range of patients with moderate-to-severe SLE. In a few subgroups, small sample sizes limited conclusions from being drawn regarding the treatment benefit with anifrolumab. Trial registration number NCT02446912 , NCT02446899 .
Intestinal Tuberculosis
Authors: Luis F. Oñate-Ocaña, Lizeth Pérez-Díaz
Journal: New England Journal of Medicine (2022)

A 36-year-old woman presented with acute-onset abdominal pain and subacute constitutional symptoms. Subdiaphragmatic free air was seen on imaging, and she was taken to the operating room, where ileal perforations were seen. Tissue cultures grew Mycobacterium tuberculosis, confirming a diagnosis of intestinal tuberculosis.
Frequency of alleles and genotypes associated with alpha-1 antitrypsin deficiency in clinical and general populations: Revelations about underdiagnosis
Authors: J.M. Hernández-Pérez, R. Ramos-Díaz, C. Vaquerizo-Pollino, J.A. Pérez
Journal: Pulmonology (2022)

Alpha-1 antitrypsin deficiency (AATD) is an underdiagnosed hereditary condition that promotes the development of lung and liver diseases, and the most common potentially life-threatening genetic condition in Caucasian adults. In this study, the clinical and genetic profile of pulmonary patients from a single center in La Palma Island (Canary Islands, Spain) was assessed to predict how to increase AATD diagnosis. AATD was tested in 1,493 pulmonary outpatients without regard to respiratory symptoms and 465 newborns. Variants of the SERPINA1 gene were characterised by real-time PCR, DNA sequencing, molecular haplotyping and phenotyping (AAT isoelectric focusing). Different respiratory pathologies were diagnosed in patients and their levels of serum AAT were measured by nephelometry. The prevalence of pneumological patients with AATD alleles was 30.5%, including PI*S, PI*Z and 6 rare genetic variants. Certain deficiency genotypes were unevenly distributed among patients diagnosed with respiratory diseases: PI*ZZ (71.4%) and PI*SS (34.8%) genotypes were more represented in patients with chronic obstructive pulmonary disease (COPD), whereas PI*MZ (27.7%) and PI*SZ (34.5%) genotypes were more abundant in patients with bronchial asthma. The estimated frequency of PI*S and PI*Z alleles in the general population was 8.2% and 2.1%, respectively. A very significant enrichment (p< 0.01) of PI*S allele, independent of the PI*Z allele, was detected in the clinical population. AATD diagnosis would improve if both the COPD and the asthmatic patients were included to screening programs. The prevalence of PI*ZZ genotype in La Palma (1/2,162) was relatively high within Spain (average 1/3,344).
Covid-19: Researchers call for routine flu testing of hospital inpatients with SARS-CoV-2 infection
Authors: Jacqui Wise
Journal: BMJ (2022)

Covid-19: Researchers call for routine flu testing of hospital inpatients with SARS-CoV-2 infection Jacqui WiseAll hospital inpatients with covid-19 should be routinely tested for influenza viruses, as those who are co-infected have much worse outcomes, researchers have said.1
Association of Tourette Syndrome and Chronic Tic Disorder With Violent Assault and Criminal Convictions
Authors: David Mataix-Cols, Suvi Virtanen, Anna Sidorchuk, Lorena Fernández de la Cruz, Henrik Larsson, Paul Lichtenstein, Antti Latvala
Journal: JAMA Neurology (2022)

Tic disorders are associated with multiple social adversities, but little is known about the experience of violent assault (including sexual assault) and criminality in this group.
EPR22-107: Evaluation of Early Risk of Moderate-to-Severe Cytokine Release Syndrome (CRS) Induced by CAR T-cell Therapy Using Pooled Clinical Trial Data
Authors: Robert R Buderi, Emelly Rusli, Vicki K Wing, Sheila S Diamond, Bhargav Koduru, Alexandru Socolov, Vibhu Agarwal, Jacob Aptekar, Rahul Jain, Aaron Galaznik, David C Fajgenbaum
Journal: Journal of the National Comprehensive Cancer Network (2022)

"EPR22-107: Evaluation of Early Risk of Moderate-to-Severe Cytokine Release Syndrome (CRS) Induced by CAR T-cell Therapy Using Pooled Clinical Trial Data" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Toxicity and efficacy of chronomodulated chemotherapy: a systematic review
Authors: Markella I Printezi, Aoife B Kilgallen, Marinde J G Bond, Urška Štibler, Marrit Putker, Arco J Teske, Maarten J Cramer, Cornelis J A Punt, Joost P G Sluijter, Alwin D R Huitema, Anne M May, Linda W van Laake
Journal: The Lancet Oncology (2022)
MICRORNA-16 MEDIATES ANTI-FIBROTIC EFFECTS OF CARDIOSPHERE-DERIVED CELLS IN RATS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
Authors: Jae Hyung Cho, Alex Rajewski, Thassio Mesquita, Ahmed Ibrahim, Russell Rogers, Isabelle Pellot, Weixin Liu, Lizbeth Sanchez, Eugenio Cingolani, Eduardo Marban
Journal: Journal of the American College of Cardiology (2022)
DEEP LEARNING MODELS FOR PREDICTION OF HEART FAILURE ADMISSIONS WITH INCORPORATION OF CLIMATE INFORMATION: SUGGESTION TOWARDS AN ADMISSION ‘FORECASTING’ SYSTEM
Authors: Takahiro Jimba, Satoshi Kodera, Shun Kohsaka, Kazumasa Harada, Yasuyuki Shiraishi, Shinji Koba, Makoto Takei, Takashi Kohno, Kenichi Matsushita, Hiroki Nakano, Tetsuro Miyazaki, Shigeto Tsukamoto, Junya Matsuda, Akito Shindo, Daisuke Kitano, Takeshi Yamamoto, Ken Nagao, Morimasa Takayama
Journal: Journal of the American College of Cardiology (2022)
Staphylococcal cassette chromosome mec amplification as a mechanism for ceftobiprole resistance in clinical methicillin-resistant Staphylococcus aureus isolates
Authors: Feiteng Zhu, Hemu Zhuang, Lingfang Di, Zhengan Wang, Yiyi Chen, Shengnan Jiang, Chao Gu, Lu Sun, Haiping Wang, Yiwei Zhu, Peng Lan, Dandan Wu, Yunsong Yu, Shujuan Ji, Yan Chen
Journal: Clinical Microbiology and Infection (2022)
CHARACTERISTIC OF OCCURRENCE OF EPSILON AND J WAVES IN VARIOUS NON CORONARY ARTERIAL RIGHT AND LEFT SIDED MYOCARDIAL DISEASES IN COMPARISON WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
Authors: Nobusada Funabashi, Kohki Nakamura, Takehito Sasaki, Shigeto Naito, Yoshio Kobayashi
Journal: Journal of the American College of Cardiology (2022)
ADVERSE EVENTS RELATED TO IMPELLA 5.0 AND IMPELLA 5.5 FROM THE MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE DATABASE
Authors: Rachel Debenham, Indranee rajapreyar, Rene J. Alvarez, Jesus Eduardo Rame, John Entwistle, Howard Todd Massey, Vakhtang Tchantchaleishvili, Konstadinos Plestis, Mahek Shah, Yevgeniy Brailovsky, David L. Fischman, Nicholas J. Ruggiero, Michael P. Savage, Praveen Mehrotra, Eric Gnall, Alec Vishnevsky
Journal: Journal of the American College of Cardiology (2022)
COMPARATIVE ANALYSIS OF METABOLIC PROFILE OF TRANSGENDER FEMALE TO MALE AND MALE TO FEMALE PATIENTS ON STEROIDS - A META-ANALYSIS
Authors: Yasar Sattar, Maria Raisat, Mohamed Zghouzi, Muhammad Aamir, Mehmood Anoosha, Akshaya Gopalakrishnan, Junaid Mir, Anees Khan, M. Chadi Alraies
Journal: Journal of the American College of Cardiology (2022)